<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145494</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/0109</org_study_id>
    <secondary_id>CCR 3923</secondary_id>
    <nct_id>NCT02145494</nct_id>
  </id_info>
  <brief_title>The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife</brief_title>
  <acronym>SPARC</acronym>
  <official_title>Stereotactic Prostate Augmented Radiotherapy With Cyberknife</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giving a higher dose of radiation to the dominant tumour nodule within the prostate is
      hypothesized to improve tumour control. This trial will assess whether this technique,
      delivered in 5 treatments, can be delivered without increasing side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim To assess if a focal boost can be delivered to the dominant tumour nodule alongside
      36.25 Gy in 5 fractions to the whole prostate gland.

      Primary end-point:   Acute toxicity (Radiation Therapy Oncology Group (RTOG), International
      prostate symptom score (IPSS))

      Secondary end-points:  Prostate specific antigen (PSA) nadir and 2-year biochemical control
      Late toxicity (IPSS, RTOG, International index of erectile function (IIEF-5)) Quality of
      life (EQ5D scale)

      Inclusion criteria

        -  Prostate cancer patients with any of the following:

        -  PSA&gt;20

        -  Gleason grade 4+3 or higher

        -  Stage T3a

        -  Exclusion criteria

        -  Nodal or metastatic disease

        -  PSA&gt;40

        -  Stage T3b or higher

      Study interventions

      This is a phase II study which will recruit 20 patients. A dose of 36.25 Gy in 5 fractions
      will be delivered to the whole prostate with a simultaneous integrated boost up to 47.5 Gy
      in 5 fractions or to the highest dose possible within dose constraints. The boost volume
      will be defined on the multiparametric magnetic resonance scan by the specialist
      radiologist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute genitourinary(GU) toxicity</measure>
    <time_frame>Maximal recorded toxicity within the acute toxicity period (up to 12 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>RTOG scale acute GU toxicity will be measured at baseline, end of treatment, then 2,4 and 12 weeks post treatment. The maximal toxicity during follow up is the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute gastrointestinal (GI) toxicity</measure>
    <time_frame>Within 12 weeks of treatment completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>RTOG scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late GI and GU toxicity</measure>
    <time_frame>From 12 weeks until study completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>RTOG scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes i.e. IPSS, IIEF-5 and EQ5-D</measure>
    <time_frame>Baseline, 12 weeks, 12 months and 6 monthly to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>IPSS, IIEF-5 and EQ5-D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical relapse-free survival</measure>
    <time_frame>Measured at 12 weeks after completion of treatment and 3-6 monthly to 5 years thereafter</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSA will be measured 3-6 monthly during study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cyberknife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Prostate cancer patients with any of the following:

          -  PSA 20-40

          -  Gleason grade 4+3 or higher

          -  Stage T3a

        Exclusion Criteria:

          -  Nodal or metastatic disease

          -  PSA&gt;40

          -  Stage T3b or higher
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas J van As, FRCR</last_name>
    <phone>02078118336</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel R Henderson, FRCR</last_name>
    <phone>02078118469</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel R Henderson, FRCR</last_name>
      <email>daniel.henderson@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nicholas J van As, FRCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison C Tree, FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SBRT (stereotactic body radiotherapy)</keyword>
  <keyword>Focal boost</keyword>
  <keyword>Prostate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
